Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority-Reference-Cited by-同舟云学术

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority

Published:2019-07-16 Issue: Volume:10 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Romano Silvia,Ferraldeschi Michela,Bagnato Francesca,Mechelli Rosella,Morena Emanuele,Caldano Marzia,Buscarinu Maria Chiara,Fornasiero Arianna,Frontoni Marco,Nociti Viviana,Mirabella Massimiliano,Mayer Flavia,Bertolotto Antonio,Pozzilli Carlo,Vanacore Nicola,Salvetti Marco,Ristori Giovanni

Publisher

Frontiers Media SA

Subject

Clinical Neurology,Neurology

Reference32 articles.

1. A much-needed focus on progression in multiple sclerosis;Thompson;Lancet Neurol,2015

2. Minocycline in MS study team. trial of minocycline in a clinically isolated syndrome of multiple sclerosis;Metz;N Engl J Med.,2017

3. Pathological mechanisms in progressive multiple sclerosis;Mahad;Lancet Neurol,2015

4. Progressive MS: from pathophysiology to drug discovery;Salvetti;Mult Scler.,2015

5. Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis:prospective combination treatment for progressive disease?;Faissner;Mult Scler.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review;Frontiers in Immunology;2023-06-02

2. Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on ‘Diagnosis, risk stratification, and continuity of care of fragility fractures’ based on a systematic literature review;Therapeutic Advances in Musculoskeletal Disease;2023-01

3. Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal;Nature Reviews Neurology;2021-01-22

4. Overcoming Compensatory Mechanisms toward Chronic Drug Administration to Ensure Long-Term, Sustainable Beneficial Effects;Molecular Therapy - Methods & Clinical Development;2020-09

5. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?;Frontiers in Immunology;2020-06-18